Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
March 19, 2024 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Corporate Update
March 12, 2024 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
February 26, 2024 16:05 ET
|
Revive Therapeutics Ltd.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE)...
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
February 01, 2024 07:30 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
January 31, 2024 17:06 ET
|
Revive Therapeutics Ltd.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE...
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
January 24, 2024 17:55 ET
|
Revive Therapeutics Ltd.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE)...
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
January 16, 2024 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
January 10, 2024 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
December 20, 2023 12:54 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
December 18, 2023 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...